INSPIRE
-
Spine
InVivo Therapeutics Announces Topline Data from Pivotal INSPIRE 2.0 Study in Acute Spinal Cord Injury
Study did not achieve primary endpoint of defined improvement on standard impairment scaleInVivo to evaluate full data set and strategic…
Read More » -
Spine
Curiteva Inc. Announces FDA 510(k) Clearance for Inspire 3D Porous PEEK HAFUSE Cervical Interbody System
Huntsville, AL based technology company, Curiteva announces the first FDA 510(k) cleared 3D printed PEEK implant, the Inspire Porous PEEK…
Read More » -
Neuro
InVivo Therapeutics Announces Publication of 12- and 24-month Data for INSPIRE 1.0 Study in Peer-Reviewed Neurosurgery
Manuscript details patient outcomes through 24-month follow up visit June 8, 2022 CAMBRIDGE, Mass.–(BUSINESS WIRE)–InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV) today…
Read More » -
Spine
InVivo Therapeutics Announces Completion of Enrollment for the INSPIRE 2.0 Acute Spinal Cord Injury Study
Topline data expected to be reported in Q1 2023 June 2, 2022 CAMBRIDGE, Mass.–(BUSINESS WIRE)–InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV),…
Read More » -
Biologics
InVivo Therapeutics Announces Sixth Patient Conversion in The INSPIRE Study of the Neuro-Spinal Scaffold™
CAMBRIDGE, Mass.–(BUSINESS WIRE)– InVivo Therapeutics Holdings Corp. (NVIV) today announced that the patient enrolled in December in the INSPIRE study of…
Read More » -
Biologics
InVivo Therapeutics Announces INSPIRE’S 29th Clinical Site: Rhode Island Hospital
January 10, 2017 CAMBRIDGE, Mass.–(BUSINESS WIRE)–InVivo Therapeutics Holdings Corp. (NVIV) today announced that Rhode Island Hospital in Providence, RI has been…
Read More » -
Biologics
InVivo Therapeutics Announces New Patient Enrollment into the INSPIRE Study
December 20, 2016 CAMBRIDGE, Mass.–(BUSINESS WIRE)–InVivo Therapeutics Holdings Corp. (NVIV) today announced that a new patient with a T8-9 fracture dislocation…
Read More » -
Biologics
InVivo Therapeutics Announces Foothills Medical Centre in Calgary, Alberta as New Canadian Site for INSPIRE Study
October 19, 2016 CAMBRIDGE, Mass.–(BUSINESS WIRE)–InVivo Therapeutics Holdings Corp. (NVIV) today announced that the Foothills Medical Centre in Calgary, Alberta has…
Read More » -
Neuro
InVivo Therapeutics Announces Fifth Patient Conversion in INSPIRE Study of the Neuro-Spinal Scaffold™
August 17, 2016 CAMBRIDGE, Mass.–(BUSINESS WIRE)–InVivo Therapeutics Holdings Corp. (NVIV) today announced that the ninth patient implanted with the Neuro-Spinal Scaffold™…
Read More » -
Biologics
InVivo Therapeutics Announces Ben Taub Hospital/Baylor College of Medicine as New Site for INSPIRE Study
July 18, 2016 CAMBRIDGE, Mass.–(BUSINESS WIRE)–InVivo Therapeutics Holdings Corp. (NVIV) today announced that the Ben Taub Hospital in Houston, TX…
Read More » -
Hospitals
InVivo Therapeutics Announces Approval for INSPIRE Pivotal Probable Benefit Clinical Study of the Neuro-Spinal Scaffold™
CAMBRIDGE, Mass.–(BUSINESS WIRE)–InVivo Therapeutics Holdings Corp. (NVIV) announced that it has received approval of a protocol amendment from the U.S. Food…
Read More » -
Hospitals
InVivo Therapeutics receives conditional FDA approval for INSPIRE pivotal probable benefit study
InVivo Therapeutics announced the FDA has given the company conditional approval to convert an ongoing study into the pivotal probable…
Read More »